Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery

Cancer Immunology Research

Volumn 5, Issue 1, 2017, Pages 29-41

  Mosely, Suzanne I S ^a   Prime, John E ^a   Sainson, Richard C A ^a,d   Koopmann, Jens Oliver ^a   Wang, Dennis Y Q ^b,e   Greenawalt, Danielle M ^b   Ahdesmaki, Miika J ^b   Leyland, Rebecca ^a   Mullins, Stefanie ^a   Pacelli, Luciano ^a,f   Marcus, Danielle ^a   Anderton, Judith ^a   Watkins, Amanda ^a   Ulrichsen, Jane Coates ^a   Brohawn, Philip ^c   Higgs, Brandon W ^c   McCourt, Matthew ^a   Jones, Hazel ^a,b   Harper, James A ^a   Morrow, Michelle ^a   Valge Archer, Viia ^a,b   Stewart, Ross ^a   Dovedi, Simon J ^a   Wilkinson, Robert W ^a   more..

^a MEDIMMUNE LTD   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c MEDIMMUNE   (United States)

^d Kymab Ltd   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; B RAF KINASE; CD45 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; GRANZYME B; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; K RAS PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROTEIN P53; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CELL INFILTRATION; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DRUG DEVELOPMENT; EXON; FLOW CYTOMETRY; GENE DOSAGE; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LUNG CANCER; MELANOMA; MICROARRAY ANALYSIS; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; PANCREAS CANCER; TRANSCRIPTOMICS; TUMOR MICROENVIRONMENT; WHOLE EXOME SEQUENCING; ANIMAL; ANTAGONISTS AND INHIBITORS; COPY NUMBER VARIATION; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; EXOME; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASM; PRECLINICAL STUDY; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; COMPARATIVE GENOMIC HYBRIDIZATION; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; EXOME; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; IMMUNOMODULATION; MICE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TUMOR MICROENVIRONMENT;

EID: 85016106905     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0114     Document Type: Article

References (55)

1. Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, et al. Fiveyear survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015;33:1191-6.
2. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-smallcell lung cancer. N Engl J Med 2015;373:123-35.
3. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50.
4. Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2016;13:143-58.
5. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61.
6. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
7. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56-61.
8. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4.
9. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
10. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
11. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.
12. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016;351:1463-9.
13. Dranoff G. Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol 2012;12:61-6.
14. Gould SE, Junttila MR, de Sauvage FJ. Translational value of mouse models in oncology drug development. Nat Med 2015;21:431-9.
15. Westcott PM, Halliwill KD, To MD, Rashid M, Rust AG, Keane TM, et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 2014;517:489-92.
16. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013;13:5.
17. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
18. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GMCSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116:1935-45.
19. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 2008;105:14987-92.
20. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102:1555-77.
21. Zhao H, Sun Z, Wang J, Huang H, Kocher JP, Wang L. CrossMap: a versatile tool for coordinate conversion between genome assemblies. Bioinformatics 2014;30:1006-7.
22. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-60.
23. Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv: Cornell University Library; 2012. Available from: https://arxiv.org/abs/1207.3907.
24. Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res 2016;44:e108.
25. Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Comput Biol 2016;12:e1004873.
26. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015;43:D805-11.
27. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012;9:357-9.
28. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012;22:568-76.
29. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.
30. Demidenko E. Statistical comparison of color cancer cell images. Oncol Rep 2006;15:1077-9.
31. Heitjan DF. Biology, models, and the analysis of tumor xenograft experiments. Clin Cancer Res 2011;17:949-51.
32. Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, et al. Identification and characterization of MEDI4736, an antagonistic anti-PDL1 monoclonal antibody. Cancer Immunol Res 2015;3:1052-62.
33. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
34. The Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
35. The Cancer Genome Atlas. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
36. Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic classification of cutaneous melanoma. Cell 2015;161: 1681-96.
37. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012;26:1131-55.
38. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 2009;30:286-92.
39. Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, et al. Autocrine effects of tumor-derived complement. Cell Rep 2014;6: 1085-95.
40. Vadrevu SK, Chintala NK, Sharma SK, Sharma P, Cleveland C, Riediger L, et al. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res 2014; 74:3454-65.
41. Sengupta S, Nandi S, Hindi ES, Wainwright DA, Han Y, Lesniak MS. Short Hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia 2010;12:837-47.
42. Kim H, Kim Y, Bae S, Kong JM, Choi J, Jang M, et al. Direct Interaction of CD40 on tumor cells with CD40L on T cells increases the proliferation of tumor cells by enhancing TGF-beta production and Th17 differentiation. PLoS One 2015;10:e0125742.
43. Shou J, Jing J, Xie J, You L, Jing Z, Yao J, et al. Nuclear factor of activated T cells in cancer development and treatment. Cancer Lett 2015;361: 174-84.
44. Twyman-Saint-Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015;520:373-7.
45. Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 2015;21: 1639-51.
46. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20.
47. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19:5300-9.
48. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012;61:1019-31.
49. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.
50. Hartmann C, Kluwe L, Lucke M, Westphal M. The rate of homozygous CDKN2A/p16 deletions in glioma cell lines and in primary tumors. Int J Oncol 1999;15:975-82.
51. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-77.
52. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, et al. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother 2013;36:477-89.
53. Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics 2014;15:190.
54. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci USA 2014; 111:11774-9.
55. Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012;72:1081-91.